The role of neuroprotection in schizophrenia

Keyphrases

• Neuroprotection 100%
• Schizophrenia 100%
• Psychosis 100%
• Olanzapine 66%
• Disease Stage 66%
• Gray Matter Loss 66%
• Therapeutic Approaches 33%
• Antipsychotics 33%
• Risperidone 33%
• Illness 33%
• High Risk 33%
• Neurodegenerative 33%
• First-episode Psychosis 33%
• First Episode 33%
• Cognitive Behavioral Therapy 33%
• Risperdal 33%
• Clozapine 33%
• Functional Outcome 33%
• Neurodevelopmental Disorders 33%
• Recent Advances 33%
• Second-generation Antipsychotics 33%
• Anatomic Pathology 33%
• Lines of Evidence 33%
• Pathophysiology of Schizophrenia 33%
• Anatomic 33%
• Absence of Evidence 33%
• Prodromal Phase 33%
• Longitudinal Course 33%
• Prodromal Symptoms 33%
• Neuroprotective Properties 33%
• Family Psychoeducation 33%
• Clinical Outcomes 33%

Neuroscience

• Neuroprotection 100%
• Gray Matter 100%
• Olanzapine 100%
• Neuroprotective Agent 50%
• Antipsychotic 50%
• Clozapine 50%
• Risperidone 50%
• Psychoeducation 50%
• Neurodevelopmental Disorder 50%
• Typical Antipsychotic 50%
• Anatomical Pathology 50%
• Cognitive Behavioral Therapy 50%